Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
BRAF V600R
Cancer:
Melanoma
Drug:
Mekinist (trametinib)
(
MEK inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
J Clin Oncol
Title:
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Excerpt:
One patient each with BRAF K601E and BRAF V600R had prolonged PR.
DOI:
10.1200/JCO.2012.43.5966
Trial ID:
NCT01037127
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login